A novel CD38 inhibitor, which has excellent in vivo efficacy, favorable pharmacokinetics, and attractive safety profile, was reported for the treatment of mitochondrial myopathy
A novel CD38 inhibitor, which has excellent in vivo efficacy, favorable pharmacokinetics, and attractive safety profile, was reported for the treatment of mitochondrial myopathy
Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd All Rights Reserved.
Click here to learn more